July 10, 2023 | Vensana Capital® Portfolio News

SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and other Chronic Ophthalmic Diseases

21

Novel FDA PMA & de novo 510k approvals

60

U.S. Commercial Product Launches

39

Level I Clinical Trials

31

Strategic Financings

31

Exits by IPO or M&A